Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2016

Open Access 01-01-2016 | Original Article

PTEN and NEDD4 in Human Breast Carcinoma

Authors: Yilun Chen, Marc J. van de Vijver, Hanina Hibshoosh, Ramon Parsons, Lao H. Saal

Published in: Pathology & Oncology Research | Issue 1/2016

Login to get access

Abstract

PTEN is an important tumor suppressor gene that antagonizes the oncogenic PI3K/AKT signaling pathway and has functions in the nucleus for maintaining genome integrity. Although PTEN inactivation by mutation is infrequent in breast cancer, transcript and protein levels are deficient in >25 % of cases. The E3 ubiquitin ligase NEDD4 (also known as NEDD4-1) has been reported to negatively regulate PTEN protein levels through poly-ubiquitination and proteolysis in carcinomas of the prostate, lung, and bladder, but its effect on PTEN in the breast has not been studied extensively. To investigate whether NEDD4 contributes to low PTEN levels in human breast cancer, we analyzed the expression of these proteins by immunohistochemistry across a large Swedish cohort of breast tumor specimens, and their transcript expression levels by microarrays. For both NEDD4 and PTEN, their transcript expression was significantly correlated to their protein expression. However, comparing NEDD4 expression to PTEN expression, either no association or a positive correlation was observed at the protein and transcript levels. This unexpected observation was further corroborated in two independent breast cancer cohorts from The Netherlands Cancer Institute and The Cancer Genome Atlas. Our results suggest that NEDD4 is not responsible for the frequent down-regulation of the PTEN protein in human breast carcinoma.
Literature
1.
Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biolumin Chemilumin 273:13375–13378
2.
Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, et al (1997) Deletion of PTEN in a patient with bannayan-riley-ruvalcaba syndrome suggests allelism with cowden disease. Am J Med Genet 71:489–493CrossRefPubMed
3.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al (1997) Germline mutations of the PTEN gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64–67CrossRefPubMed
4.
Hobert JA, Eng C (2009) PTEN hamartoma tumor syndrome: an overview. Genitourin Med 11:687–694CrossRef
5.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947CrossRefPubMed
6.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362CrossRefPubMed
7.
Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424–430CrossRefPubMed
8.
Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805–811
9.
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559CrossRefPubMed
10.
11.
12.
13.
Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, et al (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40:102–107PubMedCentralCrossRefPubMed
14.
15.
Drinjakovic J, Jung H, Campbell DS, Strochlic L, Dwivedy A, Holt CE (2010) E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron 65:341–357PubMedCentralCrossRefPubMed
16.
Goh CP, Low LH, Putz U, Gunnersen J, Hammond V, Howitt J, et al (2013) Ndfip1 expression in developing neurons indicates a role for protein ubiquitination by Nedd4 E3 ligases during cortical development. Neurosci Lett 555:225–230CrossRefPubMed
17.
Guo H, Qiao G, Ying H, Li Z, Zhao Y, Liang Y, et al (2012) E3 ubiquitin ligase Cbl-b regulates pten via Nedd4 in T cells independently of its ubiquitin ligase activity. Cell Rep 1:472–482PubMedCentralCrossRefPubMed
18.
Chung S, Nakashima M, Zembutsu H, Nakamura Y (2011) Possible involvement of NEDD4 in keloid formation; its critical role in fibroblast proliferation and collagen production. Proc Jpn Acad Ser B Phys Biol Sci 87:563–573PubMedCentralCrossRefPubMed
19.
Shi Y, Wang J, Chandarlapaty S, Cross J, Thompson C, Rosen N, et al (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21:522–527PubMedCentralCrossRefPubMed
20.
Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, et al (2010) Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 177:2622–2634PubMedCentralCrossRefPubMed
21.
Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, et al (2014) p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ 21:146–160PubMedCentralCrossRefPubMed
22.
Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128:141–156PubMedCentralCrossRefPubMed
23.
Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, et al (2008) The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 105:8585–8590PubMedCentralCrossRefPubMed
24.
25.
Yang Z, Yuan XG, Chen J, Lu NH (2012) Is NEDD4-1 a negative regulator of phosphatase and tensin homolog in gastric carcinogenesis? World J Gastroenterol 18:6345–6348PubMedCentralCrossRefPubMed
26.
Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA, et al (2013) NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cell Signal 25:12–18CrossRefPubMed
27.
Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104:7564–7569PubMedCentralCrossRefPubMed
28.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMed
29.
van 't Veer, LJ, Dai, H, van de Vijver, MJ, He, YD, Hart, AA, Mao, M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
30.
Ahn Y, Hwang CY, Lee SR, Kwon KS, Lee C (2008) The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4. Biochem J 412:331–338CrossRefPubMed
Metadata
Title
PTEN and NEDD4 in Human Breast Carcinoma
Authors
Yilun Chen
Marc J. van de Vijver
Hanina Hibshoosh
Ramon Parsons
Lao H. Saal
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-015-9971-2

Other articles of this Issue 1/2016

Pathology & Oncology Research 1/2016 Go to the issue

Original Article

Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma

Original Article

Epidemiological, Clinicopathological and Virological Features of Merkel Cell Carcinomas in Medical Center of University of Pécs, Hungary (2007–2012)

Original Article

Clinicopathological Variation of Lauren Classification in Gastric Cancer

Original Article

Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer

Original Article

Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis

Original Article

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits